Prader-Willi Syndrome Pipeline Study, H1 2020 - Analysis by Stage of Development, Drug Target, Mechanism of Action, Route of Administration and Molecule Type

DUBLIN, Jan. 24, 2020 /PRNewswire/ -- The "Prader-Willi Syndrome (PWS) - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

This report provides an overview of the Prader-Willi Syndrome (PWS) (Genetic Disorders) pipeline landscape.

The Pharmaceutical and Healthcare latest pipeline guide Prader-Willi Syndrome (PWS) - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Prader-Willi Syndrome (PWS) (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Prader-Willi Syndrome (PWS) (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Prader-Willi Syndrome (PWS) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 5, 5, 5 and 3 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 2 molecules, respectively.

Prader-Willi Syndrome (PWS) (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Report Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Prader-Willi Syndrome (PWS) (Genetic Disorders).
• The pipeline guide reviews pipeline therapeutics for Prader-Willi Syndrome (PWS) (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Prader-Willi Syndrome (PWS) (Genetic Disorders) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Prader-Willi Syndrome (PWS) (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Prader-Willi Syndrome (PWS) (Genetic Disorders).

Reasons to Buy

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Prader-Willi Syndrome (PWS) (Genetic Disorders).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Prader-Willi Syndrome (PWS) (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Key Topics Covered

1. Introduction
2. Prader-Willi Syndrome (PWS) - Overview
3. Prader-Willi Syndrome (PWS) - Therapeutics Development
4. Prader-Willi Syndrome (PWS) - Therapeutics Assessment
5. Prader-Willi Syndrome (PWS) - Companies Involved in Therapeutics Development
6. Prader-Willi Syndrome (PWS) - Drug Profiles
7. Prader-Willi Syndrome (PWS) - Dormant Projects
8. Prader-Willi Syndrome (PWS) - Discontinued Products
9. Prader-Willi Syndrome (PWS) - Product Development Milestones
10. Appendix

Companies Mentioned

• Auris Medical Holding Ltd.
• Benuvia Therapeutics Inc.
• Bioprojet SCR
• Chong Kun Dang Pharmaceutical Corp.
• ConSynance Therapeutics Inc.
• Ferring International Center S.A.
• GLWL Research Inc.
• Helsinn Group
• LG Chem Ltd.
• Lipidio Pharmaceuticals Inc.
• Millendo Therapeutics Inc.
• Neuracle Science Co. Ltd.
• OptiNose US Inc.
• Rhythm Pharmaceuticals Inc.
• Saniona AB
• Soleno Therapeutics Inc.

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/hx600r

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets